ArticleAnnals of medicine and surgery (2012)2025

Taletrectinib in ROS1-positive NSCLC: bridging clinical trials and real-world practice.

Fatima-Tuz Zahra et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.